Skip to content

Study · Randomized controlled trial · 2004

4 results

Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Buxton EC, Yao W, Lane NE

The Journal of clinical endocrinology and metabolism1 Jul 2004Cited by 62 (Europe PMC)

PMID15240611 (opens in a new tab)DOI10.1210/jc.2003-032066 (opens in a new tab)PepBankPUB-15240611
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, hPTH increased serum sRANKL within one month, with elevation throughout therapy.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, hPTH raised serum sRANKL from baseline throughout treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum sRANKL
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U (approximately 40 microg) daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    hPTH (1-34) caused a rapid and significant increase in sRANKL within 1 month, and the levels remained elevated throughout the duration of therapy.
    1 context sentence
    Summary · context
    Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone.
  2. 02HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, IL-6 increased within one month of hPTH therapy, then returned to baseline.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, hPTH raised IL-6 from baseline, but levels later returned to baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum IL-6
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U (approximately 40 microg) daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    IL-6 and IL-6sR increased significantly within 1 month, but returned to baseline levels more rapidly.
    1 context sentence
    Summary · context
    Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone.
  3. 03HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, IL-6sR increased within one month of hPTH therapy, then returned to baseline.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, hPTH raised IL-6sR from baseline, but levels later returned to baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum IL-6sR
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U (approximately 40 microg) daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    IL-6 and IL-6sR increased significantly within 1 month, but returned to baseline levels more rapidly.
    1 context sentence
    Summary · context
    Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone.
  4. 04HumanRandomized controlled trialMechanism

    In women with glucocorticoid-induced osteoporosis, hPTH mildly suppressed OPG beginning six months after therapy.

    In plain wordsIn women with glucocorticoid-induced osteoporosis, OPG decreased mildly from baseline after hPTH therapy.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum OPG
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 U (approximately 40 microg) daily · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In contrast, OPG was mildly suppressed beginning 6 months after hPTH therapy.
    1 context sentence
    Summary · context
    Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.